Total Payments
$14,466
2024 Payments
$2,890
Companies
21
Transactions
59
Medicare Patients
1,731
Medicare Billing
$263,949
Payment Breakdown by Category
Consulting$11,822 (81.7%)
Food & Beverage$2,332 (16.1%)
Other$250.00 (1.7%)
Education$62.20 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $11,822 | 13 | 81.7% |
| Food and Beverage | $2,332 | 43 | 16.1% |
| Honoraria | $250.00 | 1 | 1.7% |
| Education | $62.20 | 2 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $4,996 | 5 | $0 (2024) |
| Seagen Inc. | $2,251 | 2 | $0 (2022) |
| Dendreon Pharmaceuticals LLC | $1,635 | 2 | $0 (2019) |
| Taiho Oncology, Inc. | $1,616 | 2 | $0 (2018) |
| Advanced Accelerator Applications | $800.00 | 1 | $0 (2017) |
| Daiichi Sankyo Inc. | $525.00 | 1 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $485.06 | 4 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $465.99 | 10 | $0 (2024) |
| ABIOMED | $391.93 | 5 | $0 (2018) |
| COMSORT, Inc | $250.00 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,890 | 20 | AstraZeneca Pharmaceuticals LP ($1,943) |
| 2023 | $3,144 | 9 | AstraZeneca Pharmaceuticals LP ($3,053) |
| 2022 | $1,524 | 4 | Seagen Inc. ($1,021) |
| 2021 | $257.01 | 3 | E.R. Squibb & Sons, L.L.C. ($215.81) |
| 2020 | $1,241 | 2 | Seagen Inc. ($1,230) |
| 2019 | $1,665 | 4 | Dendreon Pharmaceuticals LLC ($1,635) |
| 2018 | $2,208 | 9 | Taiho Oncology, Inc. ($1,616) |
| 2017 | $1,536 | 8 | Advanced Accelerator Applications ($800.00) |
All Payment Transactions
59 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $8.23 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $18.98 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: Oncology | ||||||
| 11/06/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $8.48 | General |
| Category: Oncology | ||||||
| 11/02/2024 | Daiichi Sankyo Inc. | ENHERTU (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $19.38 | General |
| 09/12/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $15.04 | General |
| Category: Oncology | ||||||
| 09/12/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $4.04 | General |
| Category: Oncology | ||||||
| 09/06/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $555.00 | General |
| 08/06/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $3.14 | General |
| Category: Oncology | ||||||
| 07/18/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $15.70 | General |
| Category: Oncology | ||||||
| 07/17/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $8.65 | General |
| Category: Oncology | ||||||
| 06/25/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $3.84 | General |
| Category: Oncology | ||||||
| 06/18/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $95.12 | General |
| 06/12/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Somatuline Depot | Food and Beverage | In-kind items and services | $4.24 | General |
| Category: Oncology | ||||||
| 05/14/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $18.12 | General |
| Category: Oncology | ||||||
| 05/14/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $16.87 | General |
| 04/24/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $16.99 | General |
| 02/29/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $1,388.00 | General |
| Category: Oncology | ||||||
| 01/11/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Somatuline Depot | Food and Beverage | In-kind items and services | $149.29 | General |
| Category: Oncology | ||||||
| 11/30/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $1,387.50 | General |
| Category: Oncology | ||||||
| 11/15/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $14.99 | General |
| Category: Hematology | ||||||
| 10/27/2023 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO | Food and Beverage | In-kind items and services | $12.85 | General |
| Category: Oncology | ||||||
| 08/01/2023 | AstraZeneca Pharmaceuticals LP | IMJUDO (Biological) | Consulting Fee | Cash or cash equivalent | $555.00 | General |
| Category: Oncology | ||||||
| 07/10/2023 | AstraZeneca Pharmaceuticals LP | IMJUDO (Biological) | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 439 | 770 | $224,365 | $71,212 |
| 2022 | 10 | 375 | 683 | $181,736 | $60,028 |
| 2021 | 10 | 465 | 842 | $218,621 | $76,257 |
| 2020 | 10 | 452 | 765 | $188,597 | $56,452 |
Total Patients
1,731
Total Services
3,060
Medicare Billing
$263,949
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 127 | 299 | $83,852 | $26,920 | 32.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 69 | 159 | $46,600 | $16,473 | 35.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 57 | 110 | $23,810 | $7,618 | 32.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 46 | 47 | $24,609 | $6,261 | 25.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 34 | 34 | $13,864 | $4,587 | 33.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 49 | 50 | $13,876 | $4,297 | 31.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 30 | 44 | $8,444 | $2,559 | 30.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 27 | 27 | $9,310 | $2,498 | 26.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 78 | 200 | $55,200 | $21,540 | 39.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 68 | 181 | $47,965 | $14,031 | 29.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 75 | 129 | $26,445 | $8,116 | 30.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 34 | 34 | $13,396 | $4,536 | 33.9% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 42 | 45 | $11,880 | $3,571 | 30.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 19 | 20 | $9,940 | $3,017 | 30.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 18 | 32 | $5,920 | $1,767 | 29.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 14 | 14 | $4,368 | $1,471 | 33.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 13 | 14 | $4,704 | $1,357 | 28.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 14 | 14 | $1,918 | $621.81 | 32.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 92 | 213 | $58,788 | $24,015 | 40.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 76 | 186 | $49,290 | $14,862 | 30.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 92 | 204 | $41,820 | $14,694 | 35.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 33 | 33 | $13,002 | $4,895 | 37.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 41 | 72 | $13,320 | $4,048 | 30.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 23 | 24 | $11,928 | $3,675 | 30.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 37 | 38 | $10,032 | $3,154 | 31.4% |
About John Rhee
John Rhee is a Hematology & Oncology healthcare provider based in Pittsburgh, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1457385197.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, John Rhee has received a total of $14,466 in payments from pharmaceutical and medical device companies, with $2,890 received in 2024. These payments were reported across 59 transactions from 21 companies. The most common payment nature is "Consulting Fee" ($11,822).
As a Medicare-enrolled provider, Rhee has provided services to 1,731 Medicare beneficiaries, totaling 3,060 services with total Medicare billing of $263,949. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Pittsburgh, PA
- Active Since 07/10/2006
- Last Updated 07/29/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1457385197
Products in Payments
- IMFINZI (Biological) $2,776
- TUKYSA (Drug) $2,251
- IMJUDO (Biological) $1,665
- PROVENGE (Drug) $1,635
- LUTATHERA (lutetium Lu 177 dotatate) (Drug) $800.00
- KEYTRUDA (Biological) $735.06
- ENHERTU (Drug) $525.00
- Impella (Device) $391.93
- OPDIVO (Biological) $370.87
- Onivyde (Drug) $191.59
- PEMFEXY (Drug) $148.80
- KYMRIAH (Biological) $84.32
- Abraxane (Drug) $54.47
- KRAZATI (Drug) $51.25
- VERZENIO (Drug) $27.54
- LUTATHERA (Drug) $15.50
- Pomalyst (Drug) $14.99
- Stivarga (Drug) $13.52
- Resolute (Device) $11.43
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Pittsburgh
Salman Fazal, M.d, M.D
Hematology & Oncology — Payments: $2.2M
Hematology & Oncology $2.2M
Cyrus Khan, M.d, M.D
Hematology & Oncology — Payments: $2.2M
Hematology & Oncology $2.2M
Dr. Alexander Barsouk, Md, MD
Hematology & Oncology — Payments: $905,454
Hematology & Oncology $905,454
Taofeek Owonikoko, M.d, M.D
Hematology & Oncology — Payments: $454,396
Hematology & Oncology $454,396
Dr. Hashem Younes, M.d, M.D
Hematology & Oncology — Payments: $451,665
Hematology & Oncology $451,665
Dr. Jason Luke, M.d, M.D
Hematology & Oncology — Payments: $431,360
Hematology & Oncology $431,360